Kings Global Biotech Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Kings Global Biotech Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $144.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Kings Global Biotech Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $144.1K Trade | TransData Nexus

Kings Global Biotech Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $144.1K Total Trade · DGFT Verified

Kings Global Biotech Limited is an Indian pharmaceutical exporter with a total trade value of $144.1K across 6 products in 3 therapeutic categories. Based on 47 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Lenvatinib ($52.2K), Everolimus ($37.7K), Olaparib ($21.6K).

Kings Global Biotech Limited — Export Portfolio & Destination Treemap

Kings Global Biotech Limited pharmaceutical export portfolio — 6 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Kings Global Biotech Limited? — Company Overview & Market Position

Kings Global Biotech Limited is a vertically integrated Indian pharmaceutical company established on June 9, 2016, in Pune, Maharashtra. The company specializes in developing, manufacturing, and marketing a diverse range of pharmaceutical products across several major therapeutic areas, including oncology, nephrology, cardiology, and gynecology. Its product portfolio encompasses branded generics, blood-related products, beta-lactam cephalosporins, vitamins, minerals, and recently, nutraceuticals and herbal products.

As of October 30, 2025, Kings Global Biotech Limited reported an authorized capital of ₹2.00 crore and a paid-up capital of ₹1.81 crore. The company is classified as a micro enterprise under the MSME Act for the financial year 2024-25. The registered office is located at Office No. 201-207, Sr. No. 418, Mittal Chambers, 2nd floor, Near Hotel Panchali, J.M.Road, Shivaji Nagar, Pune - 411005, Maharashtra, India.

What Does Kings Global Biotech Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Lenvatinib$52.2K 2

Product Portfolio — Top 6 by Export Value

Kings Global Biotech Limited exports 6 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Lenvatinib	Advanced Oncology	$52.2K	12	2.4%	7
2	Everolimus	Immunosuppressants	$37.7K	4	0.1%	9
3	Olaparib	Advanced Oncology	$21.6K	4	2.3%	7
4	Vinblastine	Oncology	$20.0K	20	2.7%	11
5	Cladribine	Advanced Oncology	$6.9K	4	3.0%	8
6	Lomustine	Advanced Oncology	$5.7K	3	5.5%	4

Kings Global Biotech Limited exports 6 pharmaceutical products across 3 therapeutic categories with a total export value of $144.1K. The top category is Advanced Oncology (60.0% of portfolio), followed by Immunosuppressants (26.2%), indicating a concentrated portfolio with the top 5 products accounting for 96.1% of total export value.

Kings Global Biotech Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Kings Global Biotech Limited operates a manufacturing facility in Pune, Maharashtra, India. The facility is WHO-GMP certified, ensuring compliance with international manufacturing standards. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic areas such as oncology, nephrology, and cardiology. The company's focus on quality and compliance underscores its commitment to delivering high-quality medicines globally.

3Key Leadership

The leadership team at Kings Global Biotech Limited comprises:

Girish Bhimrao Jaiwal: Director since June 9, 2016.

Manodnya Shashank Sapre: Whole-Time Director since March 14, 2020.

Kartiki Ramesh Tupe: Additional Director since September 28, 2022.

These leaders bring a wealth of experience and strategic vision to the company, driving its growth and expansion in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Kings Global Biotech Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Kings Global Biotech Limited has made significant strides in regulated markets, obtaining certifications such as WHO-GMP, EU GMP, and ISO, which facilitate its entry into various international markets. The company's product portfolio, including oncology injectables and orphan drugs, aligns with the stringent requirements of these markets, enhancing its competitiveness. While specific regulatory filings and approvals in the US, EU, UK, Australia, and Japan are not detailed, the company's certifications and product offerings suggest a strategic focus on these regions.

2Emerging Markets

Kings Global Biotech Limited has expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification enables it to meet international manufacturing standards, facilitating access to these regions. By offering a diverse product range, including oncology injectables and orphan drugs, the company addresses the healthcare needs of these markets, positioning itself as a reliable supplier of essential medicines.

3Geographic Strategy

Kings Global Biotech Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Kings Global Biotech Limited's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. However, the company's WHO-GMP certification indicates adherence to international manufacturing standards, which is a prerequisite for FDA approvals. The absence of publicly available FDA-related information suggests that the company may be in the process of seeking approvals or has not yet pursued them.

2WHO & EU GMP

Kings Global Biotech Limited holds WHO-GMP and EU GMP certifications, reflecting its commitment to maintaining high manufacturing standards. These certifications are crucial for accessing regulated markets and demonstrate the company's dedication to quality and compliance. The EU GMP certification, in particular, enhances the company's credibility and facilitates partnerships with European distributors and healthcare providers.

3CDSCO & Indian Regulatory

Kings Global Biotech Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility in Pune is WHO-GMP certified, indicating compliance with international standards. While specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available, the company's certifications suggest adherence to Indian regulatory requirements.

Kings Global Biotech Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Kings Global Biotech Limited operates in a competitive landscape with several key players in the pharmaceutical industry. While specific competitors are not detailed, the company's focus on branded generics, oncology injectables, and orphan drugs positions it in direct competition with other manufacturers specializing in these areas. The company's WHO-GMP and EU GMP certifications provide a competitive edge, enabling it to meet international standards and access regulated markets.

2Key Differentiators

Kings Global Biotech Limited's key differentiators include its vertically integrated operations, encompassing the development, manufacturing, and marketing of a broad range of pharmaceutical products. The company's focus on branded generics and specialty medicines, such as oncology injectables and orphan drugs, addresses specific therapeutic needs. Its WHO-GMP and EU GMP certifications underscore its commitment to quality and compliance, facilitating access to international markets.

3Strategic Position

Kings Global Biotech Limited's current strategic direction emphasizes the development and marketing of branded generics and specialty medicines, including oncology injectables and orphan drugs. The company's expansion into nutraceuticals and herbal products reflects its adaptability and responsiveness to market trends. Looking ahead, the company aims to strengthen its position in both regulated and emerging markets by leveraging its manufacturing capabilities and certifications to deliver high-quality, affordable healthcare solutions globally.

Buyer Due Diligence Brief — Evaluating Kings Global Biotech Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Kings Global Biotech Limited has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, as evidenced by its 47 shipments totaling $144K USD in export value between 2022 and 2026. The company's portfolio includes six products across three therapeutic categories, with a concentration of 96.1% in its top five products. This indicates a focused approach to product development and market penetration. The company's WHO-GMP and EU GMP certifications further attest to its reliability and adherence to international manufacturing standards.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

FDA Approval: Confirm through the FDA's official website or contact the company directly.

WHO-GMP Certification: Verify via the World Health Organization's official website or request documentation from the company.

Frequently Asked Questions — Kings Global Biotech Limited

How many pharmaceutical products does Kings Global Biotech Limited export from India?

Kings Global Biotech Limited exports 6 pharmaceutical products across 3 therapeutic categories. The top exports are Lenvatinib ($52.2K), Everolimus ($37.7K), Olaparib ($21.6K), Vinblastine ($20.0K), Cladribine ($6.9K). Total export value is $144.1K.

What is Kings Global Biotech Limited's total pharmaceutical export value?

Kings Global Biotech Limited's total pharmaceutical export value is $144.1K, based on 47 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Kings Global Biotech Limited cover?

Kings Global Biotech Limited exports across 3 therapeutic categories. The largest are Advanced Oncology (60.0%, 4 products), Immunosuppressants (26.2%, 1 products), Oncology (13.8%, 1 products).

Get Full Kings Global Biotech Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.